A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 (a HER3-targeting ADC) in Patients with Advanced/metastatic Solid Tumors